

**MUSERLIAN, LUCAS AND MERCANTI, LLP**

ATTORNEYS AT LAW

INTELLECTUAL PROPERTY

600 THIRD AVENUE, NEW YORK, NY 10016

CHARLES A. MUSERLIAN  
DONALD C. LUCAS  
MICHAEL N. MERCANTISAPNA D. GADHIA  
OF COUNSEL  
OTHO B. ROSS  
LAURENCE MANBER, Ph.D.  
NU ONLYTELEPHONE  
(212) 661-8000+  
TELEPIERSG3 Fax: (212) 661-8002  
G4 Fax: (212) 867-0054E-MAIL  
info@milm patent.us  
URL: http://www.milm patent.us**TELECOPIER COVER SHEET**Date: 2-6-02Pages (Including this sheet) 2Our Reference: G161-027Your Reference: 09/284/147Attention: Ms. Qazi**FAX RECEIVED**

FEB 6 2003

**OFFICIAL** GROUP 1600**NOTICE**

Information contained in this facsimile message is attorney privileged and confidential information intended only for the use of the individual or entity referred to herein. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of the communication is strictly prohibited. If you received this communication in error, please immediately notify us by telephone and return the original message to us at the above address via U.S. Postal Service.

**REMARKS**

*Please review and then telephone me*

*Muserlian*

*Initials & X  
X for response  
3/5/03*

New Jersey Office: 105 Lock Street, Suite 203, Newark, NJ 07103 - Tel.: (973) 621-0660 Fax: (973) 621-0774

I will agree for redrafting claims 34 and 27 in the following manner

A method for treating estrogenic deficiencies in women while further avoiding the occurrence of osteoporosis, with drawal bleeding and cardiovascular diseases in post-menopausal women, without any androgenic effect and no deleterious effects in blood vessels comprising continuously without interruption administering to said women, a combination of 0.5 to 3 mg of an estrogenic compound selected from the group consisting of estradiol, esterified estradiol and equine conjugated estrogens and 1.5 to 3.75 mg of Norgestrel acetate.

-Claim 27 will be cancelled